Høglund R, Torsetnes S, Lossius A, Bogen B, Homan E, BREMEL R, et al. Human Cysteine Cathepsins Degrade Immunoglobulin G In Vitro in a Predictable Manner. Int J Mol Sci. 2019;20: pubmed publisher

Dana D, Garcia J, Bhuiyan A, Rathod P, Joo L, Novoa D, et al. Cell penetrable, clickable and tagless activity-based probe of human cathepsin L. Bioorg Chem. 2019;85:505-514 pubmed publisher

Blau R, Epshtein Y, Pisarevsky E, Tiram G, Israeli Dangoor S, Yeini E, et al. Image-guided surgery using near-infrared Turn-ON fluorescent nanoprobes for precise detection of tumor margins. Theranostics. 2018;8:3437-3460 pubmed publisher

Schaal J, Tran D, Subramanian A, Patel R, Laragione T, Roberts K, et al. Suppression and resolution of autoimmune arthritis by rhesus ?-defensin-1, an immunomodulatory macrocyclic peptide. PLoS ONE. 2017;12:e0187868 pubmed publisher

Lee C, Stankowski J, Chew J, Cook C, Lam Y, Almeida S, et al. The lysosomal protein cathepsin L is a progranulin protease. Mol Neurodegener. 2017;12:55 pubmed publisher

Zhao X, Howell K, He S, Brannan J, Wec A, Davidson E, et al. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell. 2017;169:891-904.e15 pubmed publisher

Piper A, Ross S, Redpath G, Lemckert F, Woolger N, Bournazos A, et al. Enzymatic cleavage of myoferlin releases a dual C2-domain module linked to ERK signalling. Cell Signal. 2017;33:30-40 pubmed publisher

Shivanna V, Kim Y, Chang K. Endosomal acidification and cathepsin L activity is required for calicivirus replication. Virology. 2014;464-465:287-295 pubmed publisher

Jiang H, Cheng X, Shi G, Hu L, Inoue A, Yamamura Y, et al. Cathepsin K-mediated Notch1 activation contributes to neovascularization in response to hypoxia. Nat Commun. 2014;5:3838 pubmed publisher

Guery L, Benikhlef N, Gautier T, Paul C, Jego G, Dufour E, et al. Fine-tuning nucleophosmin in macrophage differentiation and activation. Blood. 2011;118:4694-704 pubmed publisher

Zou F, Schäfer N, Palesch D, Brücken R, Beck A, Sienczyk M, et al. Regulation of cathepsin G reduces the activation of proinsulin-reactive T cells from type 1 diabetes patients. PLoS ONE. 2011;6:e22815 pubmed publisher

Gonzalez R, Seurynck Servoss S, Crowley S, Brown M, Omenn G, Hayes D, et al. Development and validation of sandwich ELISA microarrays with minimal assay interference. J Proteome Res. 2008;7:2406-14 pubmed publisher

Hamilton G, Colbert J, Schuettelkopf A, Watts C. Cystatin F is a cathepsin C-directed protease inhibitor regulated by proteolysis. EMBO J. 2008;27:499-508 pubmed publisher

Burster T, Marin Esteban V, Boehm B, Dunn S, Rotzschke O, Falk K, et al. Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions. Biochem Pharmacol. 2007;74:1514-23 pubmed

Methot N, Rubin J, Guay D, Beaulieu C, Ethier D, Reddy T, et al. Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem. 2007;282:20836-46 pubmed

Cheng T, Hitomi K, van Vlijmen Willems I, de Jongh G, Yamamoto K, Nishi K, et al. Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. J Biol Chem. 2006;281:15893-9 pubmed

Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006;20:543-56 pubmed